SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-...
SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES -- Collaboration advances Silence’s proprietary platform in the growing field of RNAi technology -- Agreement …